Jorge Nieva, MD, Discusses the Impact of IMpower010 and New Trials in Progress for Early-Stage NSCLC

Video

CancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Jorge Nieva, MD, from Keck School of Medicine of University of Southern California, about how IMpower010 (NCT02486718) made a big impact at this year’s meeting. The trial examined atezolizumab (Tecentriq) and compared it with best supportive care therapy after adjuvant chemotherapy in patients with resected early-stage non–small cell lung cancer. Results from this study indicated that the trial met its primary end point of disease-free survival superiority with atezolizumab (HR, 0.79; 95% CI, 0.64-0.96; 2-sided P = .0205), with overall survival data still immature.

Transcript:

I’m a lung cancer doctor, [and I’m most excited about IMpower010]. I think this will be the biggest splash that comes out [ASCO]. There’s going to be 6 trials in the works asking the same question [of how will adjuvant therapy affect early stage NSCLC]. They’re all going to come out sometime later. I don’t think any of those 6 trials are reporting out at ASCO.

Reference

Wakelee H, Altorki N, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):8500. doi: 10.1200/JCO.2021.39.15_suppl.8500

Recent Videos
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
4 experts in this video
4 experts in this video
Related Content